SEARCH

SEARCH BY CITATION

REFERENCES

  • Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, Avramis VI, Louie SG, Butturini A, Heisterkamp N, Mittelman SD. 2009. Adipocytes impair leukemia treatment in mice. Cancer Res 69(19): 78677874.
  • Chen J. 2008. Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nat Clin Pract Gastroenterol Hepatol 5(6): 306307.
  • Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ, Wolmark N. 2006. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98(22): 16471654.
  • Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M, Nakajima N, Watanabe M, Kubota N, Yamauchi T, Kadowaki T, Wada K, Nakagama H, Nakajima A. 2008. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 57(11): 15311538.
  • Hsieh HG, Loong CC, Lin CY. 2002. Interleukin-17 induces src/MAPK cascades activation in human renal epithelial cells. Cytokine 19: 159174.
  • Huang XF, Chen J. 2009a. Adiponectin and signal pathways in obesity-induced colon cancer: Comment on “adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition.” Gut 58(8): 1169.
  • Huang XF, Chen J. 2009b. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev 10(6): 610616.
  • Jacobs ET, Martínez ME, Alberts DS, Jiang R, Lance P, Lowe KA, Thompson PA. 2007. Association between body size and colorectal adenoma recurrence. Clin Gastroenterol Hepatol 5(8): 982990.
  • Jaffe T, Schwartz B. 2008. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer J Int Cancer 123(11): 25432556.
  • Kim S, Lee TJ, Leem J, Choi KS, Park JW, Kwon TK. 2008a. Sanguinarine-induced apoptosis: Generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. J Cell Biochem 104(3): 895907.
  • Kim S, Lee TJ, Park JW, Kwon TK. 2008b. Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells. J Cell Biochem 105(4): 971979.
  • Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. 2009. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9): 38423849.
  • Lee S, Choi EJ, Jin C, Kim DH. 2005. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97(1): 2634.
  • Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S. 2009. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 9(3).
  • Mitchell C, Kabolizadeh P, Ryan J, Roberts JD, Yacoub A, Curiel DT, Fisher PB, Hagan MP, Farrell NP, Grant S, Dent P. 2007. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Mol Pharmacol 72(3): 704714.
  • Roberts DL, Dive C, Renehan AG. 2009. Biological mechanisms linking obesity and cancer risk: New perspectives. Annu Rev Med 61: 301316.
  • Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, Starcevic V, Trajkovic V, Micic D. 2009. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond) 33(1): 151156.
  • Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P, Al-Kuraya KS. 2009. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 8(74).
  • Uddin S, Bavi P, Siraj A, Ahmed M, Al-Rasheed M, Hussain A, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Abubaker J, Bu R, Al-Kuraya K. 2010. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer 17(1): 191202.